Phase III FLAURA Trial in NSCLC

Phase III FLAURA Trial in NSCLC

Cancer-News

3 months
31 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC.

________

28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib

TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or death

AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for TAGRISSO versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC) treatments in this setting (HR 0.799 [95% CI, 0.641-0.997], p=0.0462).

TAGRISSO delivered a median OS of 38.6 months versus 31.8 months for the comparator arm. At three years, 28% of patients in the TAGRISSO arm and 9% of patients in the comparator arm remained on 1st-line study treatment. TAGRISSO also showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system (CNS) disease progression, increasing the time patients with CNS metastases lived without CNS disease progression or death (HR 0.48 [95% CI, 0.26-0.86], p=0.014).1

The results were presented at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2019 Congress in Barcelona, Spain (Abstract #LBA5_PR).

José Baselga, Executive Vice President, Oncology R&D said: “TAGRISSO has set a new benchmark in EGFR-mutated non-small cell lung cancer by demonstrating a median overall survival of more than three years. We have not before seen survival benefits of this magnitude in any global Phase III trial with any such therapy. The ground-breaking data reaffirm the benefit of using TAGRISSO first and further support its use as the 1st-line standard of care in this setting.”

Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial from Winship Cancer Institute of Emory University, Atlanta, US, said: “The results of the FLAURA trial provide further evidence to support the role of osimertinib as the preferred 1st-line therapy option for patients with EGFR-mutated non-small cell lung cancer. It is highly noteworthy that 28% of patients are still being treated with 1st-line osimertinib at three years versus 9% on either gefitinib or erlotinib.”

Read here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years-09282019.html

Up Next Autoplay
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Category: News
2 Views
Cancer-News 1 day
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Category: Head and Neck Cancers
2 Views
Cancer-News 2 days
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
5 Views
Cancer-News 3 days
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 3 days
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
13 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 6 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 6 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 6 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
2 Views
Cancer-News 6 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
11 Views
Cancer-News 6 days